10x Genomics and Lausanne University Hospital Launch Multi-Year Collaboration to Advance Single-Cell and Spatial Diagnostics in Oncology
核心洞察
10x Genomics (搜索) and Lausanne University Hospital (CHUV) (搜索) announced a multi-year research collaboration to identify biomarkers predictive of treatment response across multiple solid tumor types using single-cell and spatial technologies.
The study will examine tumor samples from hundreds of patients with non-small cell lung cancer (搜索), breast cancer (搜索), bladder cancer (搜索), and melanoma (搜索) using the Flex Apex, Xenium, and potentially Atera platforms.
Researchers aim to integrate single-cell and spatial biology data with clinical outcomes to understand mechanisms of response and resistance to antibody-drug conjugates (搜索), bispecific antibodies (搜索), and immune checkpoint inhibitors (搜索).
PLEASANTON, Calif., July 29, 2026 — 10x Genomics (搜索), Inc. (Nasdaq: TXG) and Lausanne University Hospital (CHUV) (搜索), one of Switzerland's leading academic medical centers, today announced a multi-year research collaboration aimed at advancing diagnostic applications of single-cell and spatial technologies for cancer care. The partnership intends to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis, and support future diagnostic development across multiple solid tumor types.
The collaboration builds on 10x Genomics (搜索)' broader strategy of partnering with leading research institutions to generate the scientific evidence needed to advance single-cell and spatial technologies toward clinical diagnostic use.
Study Design and Technology Platforms
The study will examine tumor samples from patients with advanced cancer who are undergoing comprehensive evaluation by a clinical molecular tumor board. Researchers plan to deploy 10x Genomics (搜索)' Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer (搜索), breast cancer (搜索), bladder cancer (搜索), and melanoma (搜索).
By integrating single-cell and spatial biology data with clinical outcomes, the investigators aim to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates (搜索), bispecific antibodies (搜索), and immune checkpoint inhibitors (搜索). The collaboration also intends to investigate how 10x single-cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.
Addressing a Growing Clinical Need
The rapid expansion of targeted therapies, immunotherapies, and other emerging treatment modalities has created new opportunities for treating patients while simultaneously increasing the complexity of treatment decision-making in oncology. This has generated a growing need for biomarkers that can help predict which patients are most likely to benefit from specific therapies, supporting more personalized treatment strategies.
"This collaboration brings together complementary expertise in spatial biology, pathology, computational AI and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment," said Raphael Gottardo, Professor and Director of the Biomedical Data Science Center at CHUV. "Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care."
Leadership Perspectives
Serge Saxonov, Co-founder and CEO of 10x Genomics (搜索), emphasized the potential of the company's technology platforms to transform oncology diagnostics. "The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient," said Saxonov. "We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care."
Expected Outcomes
The collaboration is expected to generate a comprehensive, multimodal resource integrating single-cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. Additionally, the partnership plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and molecular tumor board decision-making.
CHUV, consistently ranked among the world's best hospitals by Newsweek, brings together clinicians, pathologists, computational scientists, and translational researchers to accelerate the development of precision medicine through multidisciplinary programs spanning cancer research, advanced imaging, digital pathology, artificial intelligence, and spatial biology.